...
首页> 外文期刊>Vaccine >Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms
【24h】

Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms

机译:治疗性HIV-1疫苗的加强剂诱导与调节机制有关的不同T细胞反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Therapeutic human immunodeficiency virus (HIV) vaccines aim to reduce disease progression by inducing HIV-specific T cells. Vacc-4x are peptides derived from conserved domains within HIV-1 p24 Gag. Previously, Vacc-4x induced T cell responses in 90% of patients which were associated with reduced viral loads. Here we evaluate the effects of Vacc-4x boosters on T cell immunity and immune regulation seven years after primary immunization. Twenty-five patients on effective antiretroviral therapy received two Vacc-4x doses four weeks apart and were followed for 16 weeks. Vacc-4x T cell responses were measured by proliferation (CFSE), INF-gamma, CD107a, Granzyme B, Delayed-Type Hypersensitivity test (DTH) and cytokines and chemokines (Luminex). Functional regulation of Vacc-4x-specific T cell proliferation was estimated in vitro using anti-IL-10 and anti-TGF-beta monoclonal antibodies. Vacc-4x-specific CD8(+) T cell proliferation increased in 80% after either the first (64%) or second (16%) booster. Only 40% remained responders after two boosters with permanently increased Vacc-4x-specific proliferative responses (p = 0.005) and improved CD8(+) T cell degranulation, IFN-gamma production and DTH. At baseline, responders had higher CD8(+) T cell degranulation (p = 0.05) and CD4(+) INF-gamma production (p = 0.01), whereas non-responders had higher production of proinflammatory TNF-alpha, IL-1 alpha and IL-1 beta (p < 0.045) and regulatory IL-10 (p = 0.07). Notably, IL-10 and TGF-beta mediated downregulation of Vacc-4x-specific CD8(+) T cell proliferation increased only in non-responders (p < 0.001). Downregulation during the study correlated to higher PD-1 expression on Vacc-4x-specific CD8+ T cells (r = 0.44, p = 0.037), but was inversely correlated to changes in Vacc4x-specific CD8(+) T cell proliferation (r = -0.52, p = 0.012). These findings show that Vacc-4x boosters can improve T cell responses in selected patients, but also induce vaccine-specific downregulation of T cell responses in others. Broad surveillance of T cell functions during immunization may help to individualize boosting, where assessment of vaccine-related immune regulation should be further explored as a potential new parameter. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
机译:治疗性人类免疫缺陷病毒(HIV)疫苗旨在通过诱导HIV特异性T细胞来减少疾病进展。 Vacc-4x是衍生自HIV-1 p24 Gag内保守结构域的肽。以前,Vacc-4x在90%的患者中诱导了T细胞反应,这与病毒载量降低有关。在这里,我们评估了初次免疫7年后Vacc-4x增强剂对T细胞免疫和免疫调节的影响。 25名接受有效抗逆转录病毒治疗的患者相隔四个星期接受两次Vacc-4x剂量,并随访16周。通过增殖(CFSE),INF-γ,CD107a,粒酶B,迟发型超敏反应(DTH)以及细胞因子和趋化因子(Luminex)来测量Vacc-4x T细胞反应。使用抗IL-10和抗TGF-β单克隆抗体在体外评估了Vacc-4x特异性T细胞增殖的功能调节。第一次(64%)或第二次(16%)加强免疫后,Vacc-4x特异性CD8(+)T细胞增殖增加了80%。在两次加强Vacc-4x特异性增殖反应(p = 0.005)并改善CD8(+)T细胞脱粒,IFN-γ产生和DTH的加强后,仅40%的反应者仍然有效。在基线时,应答者的CD8(+)T细胞脱粒率更高(p = 0.05)和CD4(+)INF-γ产生(p = 0.01),而无应答者的促炎性TNF-alpha,IL-1 alpha产生更高。 IL-1 beta(p <0.045)和调节性IL-10(p = 0.07)。值得注意的是,IL-10和TGF-β介导的Vacc-4x特异性CD8(+)T细胞增殖的下调仅在无反应者中增加(p <0.001)。研究期间的下调与Vacc-4x特异性CD8 + T细胞上PD-1的较高表达相关(r = 0.44,p = 0.037),但与Vacc4x特异性CD8(+)T细胞增殖的变化呈负相关(r = -0.52,p = 0.012)。这些发现表明,Vacc-4x增强剂可以改善选定患者的T细胞反应,但在其他患者中也可以诱导疫苗特异性下调T细胞反应。免疫期间广泛监测T细胞功能可能有助于增强免疫力,因此应进一步探索评估疫苗相关免疫调节作为潜在的新参数。 (C)2013作者。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号